Outcomes of Selective Laser Trabeculoplasty for Sustained Elevation of Intraocular Pressure Following Intravitreal Anti-VEGF Injections
Authors:
Open Access
- 1 July 2026
- journal article
- research article
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 20, 1-11
Abstract
Purpose: To evaluate the efficacy and predictors of success of selective laser trabeculoplasty (SLT) for sustained elevation of intraocular pressure (SE-IOP) associated with anti-vascular endothelial growth factor (VEGF) therapy. Design: Retrospective observational case series. Methods: A retrospective chart review was performed for patients who received SLT following one or more anti-VEGF injections at an academic center between January 2013 and June 2022. Exclusionary criteria included history of non-open-angle glaucoma, incisional glaucoma surgery, or SLT more than 24 months after anti-VEGF injections. Main Outcome Measures: Outcomes included mean IOP and medication use up to 24 months following SLT. Failure was defined as less than 20% IOP reduction, increase in medication use, or need for additional laser or surgical interventions. Results: Thirty-three eyes of 31 patients were identified. Baseline IOP was 25.1 ± 6.1 mmHg on 2.7 ± 1.3 medications. SLT significantly reduced mean IOP but not medication use at all recorded time frames. At 24 months, mean IOP was 17.5 ± 8.2 mmHg (P = 0.009) on 3.1 ± 0.9 medications (P = 0.313). Success rates were 48.5% at 6 months, 32.3% at 12 months, and 23.6% at 24 months. The frequency of anti-VEGF injections (HR: 1.318; 95% CI: 1.072 to 1.623; P = 0.008) was the only significant predictor of SLT success in the multivariate analysis. Conclusion: SLT may be an effective adjunctive therapy for SE-IOP associated with anti-VEGF injections. The frequency of anti-VEGF injections prior to SLT may be a key predictor of treatment success.Keywords
This publication has 48 references indexed in Scilit:
- Persistent Ocular Hypertension Following Intravitreal Bevacizumab and Ranibizumab InjectionsJournal of Ocular Pharmacology and Therapeutics, 2010
- Sustained Elevation in Intraocular Pressure Associated With Intravitreal Bevacizumab InjectionsOphthalmic Surgery, Lasers and Imaging Retina, 2009
- Persisent ocular hypertension following intravitreal ranibizumabGraefe's Archive for Clinical and Experimental Ophthalmology, 2008
- Intravitreal bevacizumab (Avastin) causing acute glaucoma: an unreported complicationEye, 2007
- Selective Laser Trabeculoplasty as Initial and Adjunctive Treatment for Open-Angle GlaucomaJournal of Glaucoma, 2006
- Long-Term Clinical Results of Selective Laser Trabeculoplasty in the Treatment of Primary Open Angle GlaucomaEuropean Journal of Ophthalmology, 2006
- Baseline IOP predicts selective laser trabeculoplasty success at 1 year post-treatment: results from a randomised clinical trialBritish Journal of Ophthalmology, 2005
- Five‐year follow up of selective laser trabeculoplasty in Chinese eyesClinical & Experimental Ophthalmology, 2004
- Selective vs argon laser trabeculoplasty: hypotensive efficacy, anterior chamber inflammation, and postoperative painEye, 2004
- Selective Laser Trabeculoplasty as Primary Treatment for Open-angle GlaucomaArchives of Ophthalmology (1950), 2003